BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PARI Aerosol Research Institute Celebrates 100 Years Of Aerosol Therapy


5/17/2006 2:02:27 PM

MIDLOTHIAN, Va., May 17 /PRNewswire/ -- This month marks PARI's 100 year anniversary in the field of aerosol therapy. Founded in 1906 in Wuppertal, Germany, PARI started out making therapeutic whirlpool baths, evolving into a company focused on helping people with respiratory diseases. Today, the PARI LC Plus and PARI LC Star reusable nebulizers are considered the Gold Standard in aerosol therapy. Numerous pharmaceutical companies have selected PARI products for inclusion in their clinical trials and regulatory approval process including Pulmicort Respules by AstraZeneca; Xopenex by Sepracor; Accuneb and DuoNeb by Dey LP; Pulmozyme by Genentech; and TOBI from Chiron. Fifteen additional clinical development programs are in progress using only PARI products.

Over the company's history, PARI developed the first plastic nebulizers that reduced reproduction costs (1933), patented nozzle technology for greater drug delivery efficiency (1953), and introduced the PARI LC PLUS -- the industry leading breath-enhanced reusable nebulizer. PARI continues to develop new and improved respiratory devices, and in 2005 won a Frost & Sullivan innovation award for the PARI Trek compact compressor.

PARI's key to success has been producing high quality, innovative products that improve the quality of life for patients and their caregivers. Privately funded, PARI will continue to lead in the development of respiratory care by leveraging their expertise in formulation development with novel, customizable product platforms such as the eFlow Electronic Nebulizer, the VibrENT aerosol system for sinuses, and Hydrate humidification technology.

About PARI

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's primary focus is to provide patients with innovative products and services that help control or prevent symptoms from respiratory diseases. PARI also develops inhalable drug products in the area of chronic lung diseases and already has several drug candidates in clinical development. PARI's worldwide headquarters is in Starnberg, Germany with a major presence in the United States and offices in Japan, United Kingdom, and China.

Online at: For breath enhanced nebulizers and compressors: www.pari.com. For eFlow and pharma development: www.paripharma.com

PARI

CONTACT: Kirsten Ayars, +1-805-452-7909, for PARI; or Geoff A. Hunziker ofeFlow LLC, +1-831-372-3580; or Werner Gutmann of PARI RespiratoryEquipment, Inc., +1-804-253-7274, ext. 701



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES